Evidence map›Paper›PMID 42051590›Full record

ReviewFrontiers in bioinformatics2026

AI-driven discovery in protein science for immunology and infectious disease research.

Mohamed Helmy, Fatma Shafei, Diogo Pellegrina, Lingling Jin, Amr Alhossary, Heather L Wilson, Tamer Mansour, Kumar Selvarajoo

Abstract readReview
In one paragraph

Review in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed HelmyVaccine and Infectious Diseases Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Fatma ShafeiBioscience Technology Program, Saskatchewan Polytechnic, Saskatoon, SK, Canada.
Diogo PellegrinaVaccine and Infectious Diseases Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Lingling JinDepartment of Computer Science, University of Saskatchewan, Saskatoon, SK, Canada.
Amr AlhossaryChemistry Department, Wesleyan University, Middletown, CT, United States.
Heather L WilsonVaccine and Infectious Diseases Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Tamer MansourDepartment of Population Health and Reproduction, University of California, Davis, Davis, CA, United States.
Kumar SelvarajooBioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial Intelligence (AI) is impacting several aspects of modern life with its ability to enhance decision-making, automate complex tasks, and generate human-like content. It is now an indispensable tool in both everyday life and academic inquiry. In particular, the rapid evolution of AI technologies, especially machine learning, deep learning, and natural language processing (NLP), has given rise to large language models (LLMs), which have transformed how we analyze, interpret, and generate text-based, structured data and unstructured data. Among these, Generative AI (GenAI) has become increasingly popular due to its capacity to create content ranging from text and code to protein sequences and molecular structures, all based on patterns found in large training datasets. GenAI tools can assist with literature reviews, writing support, data processing, hypothesis generation, and code or visualization tasks, although outputs require critical oversight to ensure accuracy and relevance. More advanced GenAI applications include the generation of synthetic data and even the design of biological molecules and materials. Within this broader context, the fields of immunology, vaccinology, and infectious diseases research are witnessing a wave of innovation driven by AI. In this review, we explore how these recent advances in GenAI, especially those based on LLMs, are being applied to immunological research, antibody design, vaccine development, infectious diseases research and pandemic preparedness. This review is structured as a scoping review, aiming to map the rapidly evolving applications of GenAI and LLMs in immunology, vaccine development, infectious disease research, and adjacent biomedical fields. Relevant studies were identified through searching PubMed, Google Scholar and preprint archives and included if they introduced, demonstrated, or benchmarked AI-based approaches with clear relevance to immunology and infectious disease, while older preprints without subsequent peer-reviewed publication were excluded. We aim to provide a comprehensive overview of current contributions, emerging tools and models, and future perspectives of GenAI in transforming how we understand and manipulate immune responses and infectious diseases. Therefore, the reported capabilities should be interpreted as indicative of potential rather than definitive performance.

Indexed as

artificial intelligencebiomedical researchdisease surveillancedrug discoverygenerative AIimmunologyinfectious diseasespandemic preparedness

Identifiers

PMID42051590
PMCPMC13111274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.